Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti‐VEGF‐A monotherapy efficacy by targeting both VEGF‐A and angiopoietin‐2 (ANG‐2), a factor strongly upregulated in vitreous fluids of patients with retinal vascular disease and exerting some of its activities in concert with VEGF‐A. Simultaneous VEGF‐A and ANG‐2 inhibition was found to reduce vessel lesion number, permeability, retinal edema, and neuron loss more effectively than either agent alone in a spontaneous choroidal neovascularization (CNV) model. We describe the generation of a bispecific domain‐exchanged (crossed) monoclonal antibody (CrossMAb; RG7716) capable of binding, neutralizing, and depleting VEGF‐A and ANG‐2. RG7716 showed greater efficacy than anti‐VEGF‐A alone in a non‐human primate laser‐induced CNV model after intravitreal delivery. Modification of RG7716's FcRn and FcγR binding sites disabled the antibodies' Fc‐mediated effector functions. This resulted in increased systemic, but not ocular, clearance. These properties make RG7716 a potential next‐generation therapy for neovascular indications of the eye. The ratio of angiopoietins ANG‐1 and ANG‐2 regulates vessel quiescence and neoangiogenesis as well as barrier function. It also acts as a switch from health to neovascular eye diseases. The ratio of angiopoietins ANG‐1 and ANG‐2 regulates vessel quiescence and neoangiogenesis as well as barrier function. It also acts as a switch from health to neovascular eye diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886 · cited 2×
“…antibodies were generated by transient transfection with the four respective plasmids (encoding the heavy and the crossed heavy chain, as well as the corresponding light and crossed light chain) using the HEK293-F system (Invitrogen Corporation) according to the manufacturer’s instructions.”
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis
Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., & Yancopoulos, G. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81813-9 · Cited by 2,847
Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., & Qin, Y. (1995) · Nature · doi:10.1038/376070a0 · Cited by 1,820
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Angiopoietin-1 protects the adult vasculature against plasma leakage
Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N., Holash, J., McDonald, D. M., & Yancopoulos, G. D. (2000) · Nature Medicine · doi:10.1038/74725 · Cited by 1,297
Dumont, D. J., Gradwohl, G., Fong, G. H., Puri, M. C., Gertsenstein, M., Auerbach, A., & Breitman, M. L. (1994) · Genes & Development · doi:10.1101/gad.8.16.1897 · Cited by 985
Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., et al. (2006) · Nature Medicine · doi:10.1038/nm1351 · Cited by 933 · cited 3×
“…used by Fiedler and colleagues to demonstrate normal TNF-ainduced leukocyte rolling in the vasculature of ANG-2-deficient mice, but that rolling cells did not firmly adhere to activated endothelium due to lower levels of adhesion molecules on the surface of endothelial cells (Fiedler et al, 2006).”
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“However, faricimab, a bispecific antiVEGF/Ang2 antibody, was reported to have greater efficacy than anti-VEGF alone in a non-human primate laser-induced CNV model (Regula et al., 2016) and has been compared to ranibizumab in phase II studies.”
MethodBispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00010-1 · Cited by 785
Self-citationTherapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Diabetic retinopathy: Looking forward to 2030
Tan, T.-E., & Wong, T. Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1077669 · Cited by 511
Wykoff, C. C., Abreu, F., Adamis, A. P., Basu, K., Eichenbaum, D. A., Haskova, Z., Lin, H., Loewenstein, A., Mohan, S., Pearce, I. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00018-6 · Cited by 504
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
Kaplon, H., & Reichert, J. M. (2021) · mAbs · doi:10.1080/19420862.2020.1860476 · Cited by 292
Joussen, A. M., Ricci, F., Paris, L. P., Korn, C., Quezada-Ruiz, C., & Zarbin, M. (2021) · Eye · doi:10.1038/s41433-020-01377-x · Cited by 290
Sahni, J., Patel, S. S., Dugel, P. U., Khanani, A. M., Jhaveri, C. D., Wykoff, C. C., Hershberger, V. S., Pauly-Evers, M., Sadikhov, S., Szczesny, P., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.023 · Cited by 285
Self-citationPathophysiology of diabetic retinopathy: The old and the new
Kusuhara, S., Fukushima, Y., Ogura, S., Inoue, N., & Uemura, A. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0182 · Cited by 250
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Khanani, A. M., Patel, S. S., Ferrone, P. J., Osborne, A., Sahni, J., Grzeschik, S., Basu, K., Ehrlich, J. S., Haskova, Z., & Dugel, P. U. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2699 · Cited by 183
Sahni, J., Dugel, P. U., Patel, S. S., Chittum, M. E., Berger, B., del Valle Rubido, M., Sadikhov, S., Szczesny, P., Schwab, D., Nogoceke, E., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2685 · Cited by 129
Self-citationGene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
New frontiers of retinal therapeutic intervention: a critical analysis of novel approaches
Nanegrungsunk, O., Au, A., Sarraf, D., & Sadda, S. R. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2066169 · Cited by 20
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
Metadata
- Authors
- Regula, J. T., Lundh von Leithner, P., Foxton, R., Barathi, V. A., Cheung, C. M. G., Bo Tun, S. B., Wey, Y. S., Iwata, D., Dostalek, M., Moelleken, J., Stubenrauch, K. G., Nogoceke, E., Widmer, G., Strassburger, P., Koss, M. J., Klein, C., Shima, D. T., & Hartmann, G.
- Venue
- EMBO Molecular Medicine
- Published
- 2016-10-14
- Volume
- 8
- Issue
- 11
- Pages
- 1265-1288
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2531065411
- Cited by
- 376
- References
- 56
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.